Skip to main content

Table 3 Multivariate analysis of prognostic factors in ovarian cancer (n = 56)

From: The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

Variable   Log-rank Wilcoxon Cox’s hazard regression
     Hazard ratio 95% CI P value
Hemoglobin (g/dL) ≥11 0.131 0.165 1 0.524-5.356 0.385
  <11    1.675   
Albumin (g/dL) ≥4.0 0.017 0.022 1 1.055-11.34 0.04
  <4.0    3.459   
LDH (IU/L) ≥200 0.107 0.131 1 0.077-0.975 0.046
  <200    0.274   
CRP (mg/dL) <0.5 0.009 0.01 1 0.757-13.47 0.114
  ≥0.5    3.192   
Lymphocytes (/μL) ≥1,200 0.688 0.499 1 0.66-7.527 0.197
  <1,200    2.229   
Neutrophil (/μL) <4,000 0.766 0.853 1 0.291-4.046 0.903
  ≥4,000    1.085   
Peritoneal metastasis Yes 0.273 0.483 1 0.137-1.038 0.059
  No    0.378   
Liver metastasis Yes 0.795 0.603 1 0.236-5.759 0.851
  No    1.165   
Ascites Yes 0.388 0.277 1 0.593-4.84 0.325
  No    1.694   
Fever after DC vaccine (°C) <38 0.657 0.72 1 0.235-3.549 0.896
  ≥38    0.913   
Erythema (mm) ≥30 0.083 0.014 1 0.647-7.73 0.203
  <30    2.236   
WT1 peptide Yes 0.959 0.608 1 0.388-13.65 0.359
  No    2.3   
MUC1 peptide Yes 0.479 0.59 1 0.324-2.752 0.917
  No    0.945